Sunday 18 October 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
39.65
1.82
−4.39%
Follow SPRB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.13 | 4.85 | 4.59 | 8.78 | |
Current Ratio |
1.54 | 5.17 | 4.67 | 9.23 | |
Net Debt/EBITDA |
1.23 | 4.41 | 4.06 | 5.62 | |
Debt/Assets |
3.52% | 0.00% | 11.51% | 6.89% | |
Debt/Equity |
0.10 | 0.00 | 0.19 | 0.08 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.65 | 0.44 | 0.71 | 1.36 | |
Capex/Depreciation |
0.00 | 0.00 | (0.04) | (0.21) | |
Interest Coverage |
(433.11) | (1,850.00) | (17.78) | (15.05) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(9.44) | (8.42) | (6.36) | (9.10) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.06) | |
Free Cash Flow per Share |
(9.44) | (8.42) | (6.37) | (9.15) | |
Cash per Share |
18.95 | 63.76 | 39.42 | 39.61 | |
Shareholders Equity per Share |
9.57 | 55.43 | 25.25 | 34.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.57 | 55.43 | 25.25 | 34.44 | |
Free Cash Flow |
(5.32) | (6.46) | (8.74) | (22.25) | |
Working Capital |
5.09 | 42.03 | 43.25 | 90.19 | |
Capital Expenditures |
— | — | (0.01) | (0.13) | |
Net Current Asset Value |
4.59 | 41.61 | 33.51 | 82.03 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.59 | 1.12 | 2.28 | 1.01 | |
Average Assets |
40.21 | 49.12 | 43.91 | 62.34 | |
Average Common Equity |
28.51 | 35.67 | 24.99 | 48.46 |
Columns are period end dates